Nutra Pharma Submits Final Packaging, Labeling To FDA For Nyloxin OTC, Nyloxin Rx

Nutra Pharma has submitted the final packaging and labeling to the FDA to begin selling Nyloxin OTC, an over-the-counter treatment for moderate-to-severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain. The company had introduced Nyloxin OTC in November.

Reportedly, Nyloxin OTC is similar to the company’s recently launched pain reliever, Cobroxin, and will be available internationally as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the company had introduced Nyloxin Rx in October as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “Completing the FDA registration for Nyloxin OTC and Nyloxin Rx is an important and required step towards introducing our Nyloxin-branded pain relievers throughout domestic and international markets.

“With the FDA registration now completed, we plan to immediately move forward with our launch of Nyloxin Rx here in the United States, while we finalize our international drug registrations in Canada, Europe and South America for both our prescription and over-the-counter formulations.”